GlassScriptPhysician profile
Sumana Gangi
NPI 1487679213
$787,120.88
in general payments reported to CMS, 2019-2025
66 companies · $52K in 2025
The $52K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $248K · 2020: $128K · 2021: $98K · 2022: $138K · 2023: $79K · 2024: $44K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150K · Travel and Lodging: $17K · Food and Beverage: $7,964 · Education: $15.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150,153.25 |
| Travel and Lodging | $17,448.95 |
| Food and Beverage | $7,964.47 |
| Education | $15.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $381,285.11 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $225,064.67 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53,237.04 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $41,045.73 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $30,272.66 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $28,326.81 | 2019-2022 | |
| Eli Lilly and Company | $12,819.62 | 2019-2025 | |
| Mannkind Corporation | $4,417.64 | 2019-2025 | Afrezza |
| Novo Nordisk As | $2,430.00 | 2020 | |
| Amgen INC. | $805.04 | 2019-2025 | Evenity, Tepezza, Prolia |
| Abbvie INC. | $780.99 | 2019-2025 | |
| Abbott Laboratories | $756.04 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Cequr Corporation | $737.99 | 2022-2025 | Cequr Simplicity |
| Dexcom, INC. | $595.65 | 2019-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $409.58 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $293.39 | 2019-2025 | Tymlos |
| Medtronic, INC. | $285.62 | 2022-2025 | Minimed 780g, Intellis Adaptivestim |
| Ibsa Pharma INC. | $248.82 | 2020-2025 | Tirosint, Licart, Flector |
| Esperion Therapeutics, INC. | $243.82 | 2020-2023 | Nexletol |
| Amneal Pharmaceuticals LLC | $222.84 | 2019-2025 | Unithroid |
| Madrigal Pharmaceuticals | $217.12 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $209.22 | 2021-2025 | |
| Amarin Pharma, INC. | $173.77 | 2019-2023 | |
| Pfizer INC. | $149.18 | 2021-2025 | |
| Grt US Holding, INC. | $140.91 | 2020-2022 | |
| Zealand Pharma US, INC. | $133.20 | 2020-2021 | |
| Corcept Therapeutics | $121.03 | 2019-2025 | Korlym |
| Becton, Dickinson and Company | $114.90 | 2021-2022 | |
| Beta Bionics, INC. | $111.08 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Insulet Corporation | $106.35 | 2019-2025 | Omnipod |
| Recordati_rare_diseases_inc. | $97.26 | 2021-2025 | Isturisa, Signifor Lar |
| Xeris Pharmaceuticals, INC. | $91.72 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Amryt Pharma Holdings LTD | $79.56 | 2022-2023 | Mycapssa |
| Verity Pharmaceuticals INC. | $69.99 | 2024-2025 | Tlando |
| Astellas Pharma US INC | $69.32 | 2023-2025 | Veozah |
| Horizon Therapeutics Plc | $63.18 | 2023 | Tepezza |
| Alexion Pharmaceuticals, INC. | $62.15 | 2021-2022 | |
| Sequel Med Tech, LLC | $61.86 | 2025 | Twiist |
| Arbor Pharmaceuticals, INC. | $58.41 | 2021 | |
| Lifescan, INC. | $53.09 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $49.41 | 2022 | |
| Intuity Medical INC | $48.87 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Ultragenyx Pharmaceutical INC. | $47.47 | 2022-2023 | |
| Nevro Corp. | $45.79 | 2022-2023 | Senza |
| Medtronic Minimed, INC. | $44.20 | 2020 | |
| Companion Medical, INC. | $37.76 | 2020 | |
| Amphastar Pharmaceuticals, INC. | $37.18 | 2023-2025 | Baqsimi |
| Vistapharm, INC. | $36.09 | 2021 | |
| Antares Pharma, INC. | $33.55 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.50 | 2022-2024 | Cycloset |
| Acerus Pharmaceuticals Corporation | $28.13 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $25.73 | 2025 | |
| Valeritas, INC. | $25.42 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.86 | 2019 | |
| Averitas Pharma INC. | $20.30 | 2023 | Qutenza |
| Acella Pharmaceuticals, LLC | $19.73 | 2023 | NP Thyroid 60 |
| Shire North American Group INC | $18.17 | 2019 | |
| Endo Pharmaceuticals INC. | $17.87 | 2020 | |
| Alfasigma USA, INC. | $16.10 | 2021 | |
| Ascensia Diabetes Care US INC. | $14.38 | 2021 | |
| Ascendis Pharma Endocrinology INC | $13.73 | 2025 | Yorvipath |
| Kowa Pharmaceuticals America, INC. | $13.25 | 2021 | |
| Echosens North America, INC. | $12.03 | 2025 | Fibroscan |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$350,669.12 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumana Gangi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.